Brief presentation

I am senior consultant neurologist at the Danish Dementia Research Centre (DDRC), and clinical research associate professor at Copenhagen University, Dept. of Clinical Medicine. My research focuses on Alzheimer´s disease and Lewy body dementia with special emphasis on biomarkers (imaging, fluid digital biomarkers), pathophysiology and early disease models especially with regards to prodromal alpha-synucleinopathies.

I am the director of the clinical trial unit at the DDRC where we carry out drug intervention studies (phase I - IV) and clinical research in Alzheimer´s disease, Huntingtons disease and related disorders.

Main research areas

My overall research area is within neurodegenerative dementia with particular emphasis on Lewy body dementia and Alzheimer's disease. My specific scientific focus area is biomarkers for early diagnostics and as outcome measures in intervention studies and investigation of pathophysiological mechanisms in neurodegenerative diseases. Further, I am interested in the development of digital markers and imaging markers and their implementation in the clinic.

Areas of interest

• Biomarkers in Lewy body dementia and Alzheimer´s disease
• Early manifestations and pathophysiology in Lewy body dementia and Alzheimer´s disease
• Clinical application of biomarkers 
• Digital biomarkers 

Potential conflicts of interest

• Springer-Nature: Dr. Frederiksen serves as Editor-in-Chief for Alzheimer´s Research & Therapy (from June 2024 – 2023- May 2024 as Associate Editor) (Personal remuneration) 
• Springer-Nature: Dr. Frederiksen is the Editor on a textbook (“Management of patients with Dementia – Role of the physician”) (Personalremuneration in the form of royalties) 
• Hans Reitzels Forlag (publisher): Dr. Frederiksen hascontributed two chapters to the book "Forstå demens”) (Personal remuneration in the form of royalties) 
• Novo Nordisk: Dr. Frederiksen serves as consultant and member of an advisory board in relation to Novo Nordisks clinical development program of GLP-1RA in Alzheimer´s disease (2021 - ongoing) (Remuneration paid to institution) 
• Roche Diagnostics: Dr. Frederiksen has served in an advisory board (2024 - ongoing) (Remuneration paid to institution) 
• Eli Lilly: Dr. Frederiksen has provided consultancy services (2024) (Remuneration paid to institution) 
• Eisai/Bioarctic: Dr. Frederiksen has provided consultancy services (2023-2025) (Remuneration paid to institution) 
• AbbVie: Dr. Frederiksen has provided consultancy services (2025) (Remuneration paid to institution)
• Speaker and educational activities: Roche (2023, 2024, 2025), Roche Diagnostics (2025, 2026) Eisai/Bioarctic (2023, 2024, 2025, 2026), Eli Lilly (2025, 2026), Novo Nordisk (2023, 2024, 2025), Lundbeck A/S (2023, 2024, 2025) (Remuneration paid to institution) 
• Speaker and educational activities: BestPractice Nordic (2024, 2025), Alzheimerforeningen (2024), Lundbeckfonden (2023), Folkeuniversitetet i Emdrup (2025, 2026), Folkeuniversitetet i Aalborg (2026), Dagens medicin (2023, 2024, 2025), MedScape (2025, 2026) (Personal remuneration) 
• Lion Bridge (Medical Language service): Dr. Frederiksen has provided consultancy services in the form of clinical review of translated clinical scales (2022 - ongoing) (Personal remuneration) 
• European Geriatric Medicines Society: Serves on the Scientific advisory board (and as lecturer) on the MiCog educational program (supported by an unrestricted grant from Nestlé) (Personal Remuneration).
• Dr Frederiksen serves (or has served) as Principal or Sub-investigator and National Coordinator on several industry-sponsored phase 2 and 3 trials (indication Alzheimer´s disease): Roche, Roche Diagnostics, Biogen, NovoNordisk, Osuka, AbbVie (2028 - ongoing) (Remuneration paid to institution) 
• Dr. Frederiksen serves or has served as member of Alzheimer forskningsfonden (2027-2025), chair – National Treatment guidelines (2024 - ongoing), co-chair – Guideline Production Group, European Academy of Neurolgy (2022 - ongoing) (No remuneration)
• Dr Frederiksen has received funding or participated in research which has received funding from the following: Alzheimer Forskningsfonden, Parkinsonforeningen, Aase og Ejner Danielsens Fond, KID fonden, Ellen Mørch Fonden, Jascha Fonden, C2N, Overretssagfører L. Zeuthens Mindefond, Kong Christian den Tiendes Mindefond, Rigshospitalets Forskningspulje, Innovationsfonden, A.P. Møller fonden, ERA-PERMED, IHI, Hertzfonden, Harboefonden, Grosserer F.L.Foghts Fond, Fonden for Neurologisk Forskning, DANMODIS, Beckett fonden.
•